Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H1ssF Vaccine vs. Seasonal Influenza Vaccine in Adults
NCT07340047Phase 1Withdrawn
- Sponsor
- University of Minnesota
- Start
- Aug 2026
- Primary completion
- Mar 2028
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
01
Overview
Phase 1, randomised, open-label trial of H1ssF in influenza (2 arms), sponsored by University of Minnesota. Primary endpoints: Occurrence of solicited local reactogenicity at 7 days, Occurrence of solicited systemic reactogenicity at 7 days and 2 more. Planned start Aug 2026; status: withdrawn.
02
Drugs
H1ssF
03
Conditions
influenza
Beyond the preview
Go deeper on NCT07340047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07340047.